Sanofi ADR (SNY)vsVuzix Corp Cmn Stk (VUZI)
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
VUZI
Vuzix Corp Cmn Stk
$3.11
+8.74%
TECHNOLOGY · Cap: $239.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 753873% more annual revenue ($47.35B vs $6.28M). SNY leads profitability with a 16.0% profit margin vs 0.0%. SNY earns a higher WallStSmart Score of 51/100 (C-).
SNY
Buy51
out of 100
Grade: C-
VUZI
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+25.0%
Fair Value
$62.70
Current Price
$43.31
$19.39 discount
Margin of Safety
+43.1%
Fair Value
$4.34
Current Price
$3.11
$1.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Revenue surging 76.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Trading at 10.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bull Case : VUZI
The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Bear Case : VUZI
The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
SNY profiles as a mature stock while VUZI is a hypergrowth play — different risk/reward profiles.
VUZI carries more volatility with a beta of 1.52 — expect wider price swings.
VUZI is growing revenue faster at 76.3% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
SNY scores higher overall (51/100 vs 26/100), backed by strong 16.0% margins. VUZI offers better value entry with a 43.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Vuzix Corp Cmn Stk
TECHNOLOGY · CONSUMER ELECTRONICS · USA
Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?